Preview

Cardiovascular Therapy and Prevention

Advanced search

Clinical and cost-effectiveness of ACE inhibitors in patients with arterial hypertension and coronary heart disease

Abstract

Aim. To compare clinical and cost-effectiveness of ACE inhibitors in patients with arterial hypertension (AH) and coronary heart disease (CHD), aiming to guide the appropriate medication selection process.

Material and methods. The study included 60 patients, receiving standard combined pharmaceutical treatment, plus perindopril, or moexipril, or fosinopril (n=20 in each group). At Day 7, all patients were administered ramipril.

Results. Clinical effectiveness of fosinopril, moexipril, perindopril and ramipril was similar: in all groups, significant blood pressure reduction was achieved by Day 6 and sustained till Day 38 of ramipril therapy. All ACE inhibitors were well-tolerated. Maximal cost-effectiveness ("minimal cost" method) was observed for ramipril.

Conclusion. Assessing clinical and cost-effectiveness of various medications from one pharmacological group could be used for developing pharmaceutical therapy standards aimed to guide the medication selection process in individual patients.

About the Authors

O. Yu. Korennova
Omsk State Medical Academy; Public Health Department, Omsk City Administration
Russian Federation


A. V. Petrenko
Omsk State Medical Academy; City Clinical Hospital No. 4. Omsk
Russian Federation


M. A. Petrenko
City Clinical Hospital No. 4. Omsk
Russian Federation


E. V. Kurt-Kovalenko
City Clinical Hospital No. 4. Omsk
Russian Federation


E. A. Turusheva
City Clinical Hospital No. 4. Omsk
Russian Federation


T. A. Natsarenus
City Clinical Hospital No. 4. Omsk
Russian Federation


S. V. Alekseeva
Public Health Department, Omsk City Administration
Russian Federation


L. G. Mashinskaya
Public Health Department, Omsk City Administration
Russian Federation


M. I. Shupina
Omsk State Medical Academy
Russian Federation


E. A. Osipova
City Clinical Hospital No. 4. Omsk
Russian Federation


References

1. Остроумова О.Д., Мамаев В.И. Фармакоэкономические аспекты лечения артериальной гипертонии. Артер гиперт 2002; 8(6): 193-9.

2. Белоусов Ю.Б., Тхостова Э.Б. Классы гипотензивных препаратов: стратегия и тактика выбора первого препарата. Сердце 2002; 5(5): 220-9.

3. Воробьев П.А., Аксентьева М.В., Юрьев А.С., Сура М.В. Клинико-экономический анализ. Ньюдиамед 2004: 404 с.

4. Приложение к Приказу Федеральной службы по надзору в сфере здравоохранения и социального развития от 02.10.2006 г. № 2240-Пр/06.

5. Петри А. Наглядная статистика в медицине. Пер. с англ. В.П. Леонова. А. Петри, К. Сэбин. Москва "ГЭОТАР МЕД" 2003; 144 с.


Review

For citations:


Korennova O.Yu., Petrenko A.V., Petrenko M.A., Kurt-Kovalenko E.V., Turusheva E.A., Natsarenus T.A., Alekseeva S.V., Mashinskaya L.G., Shupina M.I., Osipova E.A. Clinical and cost-effectiveness of ACE inhibitors in patients with arterial hypertension and coronary heart disease. Cardiovascular Therapy and Prevention. 2008;7(4):41-44. (In Russ.)

Views: 462


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)